– PRIMROSE 1 and PRIMROSE 2, pivotal Phase 3 clinical trials to assess efficacy and safety of novel oral GnRH…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
Annual Report 2016
ObsEva SA at the Needham Annual Healthcare Conference
Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor–Mediated Signaling in Human Amnion and Myometrium
Sung Hye Kim, Oliver Pohl, Andre Chollet, Jean-Pierre Gotteland, Adam D. J. Fairhurst, Phillip R. Bennett, and Vasso Terzidou
THE ‘ART’ OF WOMEN’S HEALTH – Add back or not add back? Obseva: Both options good as UF, endo trials continue
THE ‘ART’ OF WOMEN’S HEALTH – Add back or not add back? Obseva: Both options good as UF, endo trials…
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
Geneva, Switzerland – 24 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Both OTR Antagonists, Atosiban and Nolasiban, Inhibits PGE2/PGF2α-Induced Contractions of Human Pregnant Myometrium In Vitro
Sung Hye Kim, Hauwa Ahmed, Lucia Riaposova, Oliver Pohl, Andre Chollet, Aylin Hanyaloglu, Phillip R Bennett, Vasso Terzidou
SRI Conference, 15-18 March 2017, Orlando, FL
Abstract S-031: Page 245A
Scientific Abstracts Reproductive Sciences Vol. 24 (1_suppl), 1A-51A, March 2017
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist – Geneva, Switzerland – 17 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company…
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
– IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer…